Spero Therapeutics (SPRO) Price to Earnings (2017 - 2026)
Spero Therapeutics' (SPRO) quarterly Price to Earnings came in at 13.46 in Q2 2026, up 85.93% on a YoY basis from 7.24 in Q2 2025, and up 28.45% quarter-over-quarter from 18.81 in Q1 2026.
Powered by 
Analysis
Spero Therapeutics (SPRO) Price to Earnings (2017 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has reported Price to Earnings for 10 consecutive years, with 13.46 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Price to Earnings rose 85.93% year-over-year to 13.46; the trailing twelve-month figure through Jun 2026 stood at 22.18 (up 829.78% YoY), and the FY2025 full-year result was 18.84, up 2396.93% from the prior year.
- Price to Earnings improved to 13.46 in Q2 2026 per SPRO's latest filing, from 18.81 in the prior quarter.
- Across five years, Price to Earnings topped out at 4.39 in Q4 2025 and bottomed at 95.62 in Q2 2025.
- Historically, Price to Earnings has averaged 11.38 across 5 years, with a median of 6.07 in 2023.
- The widest YoY moves for Price to Earnings: up 258.63% in 2025, down 2332.82% in 2025.
- Over 5 years, Price to Earnings stood at 2.43 in 2022, then plunged by 37.34% to 1.52 in 2023, then tumbled by 281.93% to 2.77 in 2024, then surged by 258.63% to 4.39 in 2025, then sank by 406.38% to 13.46 in 2026.
- According to Business Quant data, Price to Earnings over the past three periods registered 13.46, 18.81, and 4.39 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Spero Therapeutics | 67.82 Mn | 17.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.46 |
| Mar 31, 2026 | -18.81 |
| Dec 31, 2025 | 4.39 |
| Sep 30, 2025 | -14.34 |
| Jun 30, 2025 | -95.62 |
| Mar 31, 2025 | -2.90 |
| Dec 31, 2024 | -2.77 |
| Sep 30, 2024 | -4.11 |
| Jun 30, 2024 | -3.93 |
| Mar 31, 2024 | -7.32 |
| Dec 31, 2023 | 1.52 |
| Sep 30, 2023 | -20.01 |
| Jun 30, 2023 | -6.40 |
| Mar 31, 2023 | -5.75 |
| Dec 31, 2022 | 2.43 |
| Sep 30, 2022 | -7.34 |
| Jun 30, 2022 | -1.00 |
| Mar 31, 2022 | -9.46 |
| Dec 31, 2021 | -18.91 |
| Sep 30, 2021 | -26.44 |